Gene therapy company Kriya Therapeutics secured a $313 million equity financing, one of 2025’s largest private biotech rounds. The funds will support the advancement of Kriya’s pipeline of nine programs targeting neurology, metabolic health, and ophthalmology, with two assets currently in clinical development. Kriya has previously raised over $430 million since 2022 and expanded its portfolio through acquisitions. CEO Shankar Ramaswamy emphasized the company’s ambition to make gene therapies mainstream by integrating research, development, and manufacturing capabilities into a cohesive engine.